FDA puts aging on its regulatory science agenda
At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that longevity is a priority. The longevity field has spent years asking what the FDA thinks of aging as an indication. On the first morning of ARDD 2026 at Harvard, it got the closest thi
<p>At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that longevity is a priority. The longevity field has spent years asking what the FDA thinks of aging as an indication. On the first morning of ARDD 2026 at Harvard, it got the closest thi</p>